Anzeige
Mehr »
Login
Montag, 26.02.2024 Börsentäglich über 12.000 News von 683 internationalen Medien
Nurexone Biologic: Spektakuläre Story – spektakulärer Kursverlauf!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 882807 | ISIN: US92532F1003 | Ticker-Symbol: VX1
Tradegate
23.02.24
19:22 Uhr
399,05 Euro
+1,60
+0,40 %
1-Jahres-Chart
VERTEX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
VERTEX PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
393,55399,9025.02.
395,55399,2523.02.

Aktuelle News zur VERTEX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrHere's Why IBD Stock Of The Day Vertex Pharmaceuticals Is Newly Actionable5
FrVertex's Kalydeco Gets CHMP Positive Opinion For Label Expansion To Cystic Fibrosis In Infants361CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Friday, Vertex Pharmaceuticals Inc. (VRTX) announced that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has...
► Artikel lesen
FrVertex seeks EMA approval for cystic fibrosis drug targeting infants7
FrVertex Pharmaceuticals Incorporated: Vertex Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older295- If approved, KALYDECO will be the first and only medicine approved in Europe to treat the underlying cause of cystic fibrosis in babies as young as 1 month with specific mutations in the CFTR...
► Artikel lesen
MiRegeneron, Vertex Pharma join $100B club in biotech12
DiWhat Analysts Are Saying About Vertex Pharmaceuticals Stock13
DiVertex Pharmaceuticals Is About to Extend Its Leadership in This Billion-Dollar Market11
17.02.Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here's Why That's a Smart Move.25
15.02.VERTEX PHARMACEUTICALS INC / MA - 10-K, Annual Report6
15.02.Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?19
14.02.EC approves Vertex/CRISPR's Casgevy gene therapy for inherited blood disorders10
14.02.Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders17
14.02.Hunting a non-opioid painkiller, a biotech startup reveals plans to chase Vertex9
14.02.Stock-Split Watch: Is Vertex Pharmaceuticals Next?15
13.02.If You Invested $10,000 in Vertex Pharmaceuticals in 2014, This Is How Much You Would Have Today5
13.02.Vertex, CRISPR gene therapy approved in EU for sickle cell disease, beta-thalassemia10
13.02.Vertex: EU Okays Casgevy For Sickle Cell Disease & Transfusion-Dependent Beta Thalassemia Treatment316CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The European Commission has granted conditional marketing authorization to Casgevy, a CRISPR/Cas9 gene-edited therapy. Casgevy is approved for the treatment...
► Artikel lesen
13.02.Vertex Pharmaceuticals Incorporated: European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia362- Over 8,000 patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia may be eligible for treatment - Vertex Pharmaceuticals Incorporated (Nasdaq:...
► Artikel lesen
12.02.Pro Research: Wall Street delves into Vertex Pharmaceuticals6
10.02.Is Vertex Pharmaceuticals Stock a Buy Now?30
Seite:  Weiter >>
291 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
4,3,21